Aileron Therapeutics to be Included in the Russell Microcap Index AUSTIN, Texas, July 1, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron" or the "Company") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications,…
Aileron Therapeutics to be Included in the Russell Microcap® Index AUSTIN, Texas , July 1, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron" or the "Company") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that the Company is set to join the Russell Microcap® Index at the conclusion of the 2024 Russell U.S. Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024. The annual Russell U.S. Indexes reconstitution captures the 4,000 largest U.S. stocks as of Tuesday, April 30th, ranking them by total market capitalization.
University of Texas/Texas A&M sells Aileron Therapeutics shares worth over $21k https://www.investing.com/news/company-news/university-of-texastexas-am-sells-aileron-therapeutics-shares-worth-over-21k-93CH-3487834
University of Texas/Texas A&M sells Aileron Therapeutics stock https://www.investing.com/news/company-news/university-of-texastexas-am-sells-aileron-therapeutics-stock-93CH-3482262
Aileron Therapeutics Announces New Interim CFO Appointment An update from Aileron Therapeutics Inc (ALRN) is now available. Aileron Therapeutics, Inc. has appointed Timothy M. Cunningham as the interim chie…
ALRN Stock Earnings: Aileron Therapeutics Reported Results for Q1 2024 Aileron Therapeutics (NASDAQ: ALRN ) just reported results for the first quarter of 2024. Aileron Therapeutics reported earnings per share of -86 cents. The company did not report any revenue for the quarter. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now. The post ALRN Stock Earnings: Aileron Therapeutics Reported Results for Q1 2024 appeared first on InvestorPlace .
Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights Announced positive data from Cohort 1 of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients with positive trends observed in seven of the eight biomarkers evaluated
Down -36.29% in 4 Weeks, Here's Why Aileron Therapeutics (ALRN) Looks Ripe for a Turnaround The heavy selling pressure might have exhausted for Aileron Therapeutics (ALRN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Aileron Therapeutics to Present at Two Upcoming Investor Conferences AUSTIN, Texas, May 06, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that Brian Windsor, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences:
Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million | ALRN Stock News Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a